Overview

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, dose-escalation study in female patients with recurrent or persistent gynecologic tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Vector Oncology
Collaborator:
GlaxoSmithKline
Treatments:
Topotecan